Like the study but a more powerful one IMO would be a retrospective one of patients that had been on V for a year versus patients not on V. See if there is a decrease in cardiac events, pulmonary embolism, stroke and ARDS type lung issues in patients with covid that had the benefit of the remodeling and anti inflammatory effects of V on the endothelium etc for at least a year. Lem-
"Obviously assuming the trial indicates efficacy or trend towards efficacy (it is only a 2 week course after all) and so justifies a more thorough, longer course of treatment. "
P.s. let us ask NIH to fund a longer Vascepa covid-19 trial just like hydrochloroquie and azithromycin.